C-Reactive Protein to Albumin Ratio is an Indicator of Poor Prognosis for Patients with Biliary Tract Cancer
Objectives: This retrospective study evaluated the prognostic significance of the ratio of C-reactive protein (CRP) to albumin (Alb) in patients with biliary tract cancer (BTC). Methods: A total of 178 patients with newly diagnosed BTC, who had been treated in our departments between January 2013 and September 2018, were enrolled in the study. All medical records were reviewed retrospectively. Patients who showed clinical evidence of infection or other inflammatory conditions were excluded. We investigated the correlation between the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), CRP to Alb ratio (CAR) and the overall survival (OS) rates for BTC patients. Both univariate and multivariate analyses were performed to identify clinicopathological variables associated with OS. Results: The optimal cutoff level for the CAR was 0.66. An elevated CAR was associated with low OS (p<0.001). In the multivariate analysis CAR, was independently associated with OS (HR 3.44, 95% CI: 2.05-5.79, p<0.001). Median OS for CAR ≤0.66 and CAR >0.66 were 22.0 months and 6.0 months, respectively. By contrast, NLR (p=0.12) and PLR (p=0.85) were not independently associated with OS. Conclusion: The CAR might be an independent prognostic marker for patients with BTC, and might have value comparable with other established inflammation-based prognostic scores. The prognostic value of this novel inflammationbased prognostic score needs to be verified in patients with other types of cancer.
1.Vasilieva LE, Papadhimitriou SI, Dourakis SP. Modern diagnostic approaches to cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2012;11:349–59. [CrossRef]
2. Imperatori M, D’Onofrio L, Marrucci E, Pantano F, Zoccoli A, Tonini G. Neoadjuvant treatment of biliary tract cancer: state of the art and new perspectives. Hepatic Oncol 2015;3:93–9.
3. Howlader N NA, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, et al. Cronin KA SEER Cancer Statistics Review 2016;1975–2013.
4. Wang SJ, Lemieux A, Kalpathy-Cramer J, Ord CB, Walker GV, Fuller CD, Kim JS, Thomas CR. Jr Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 2011;29:4627–32. [CrossRef]
5. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophillymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013;88:218–30. [CrossRef]
6. Park JH, Watt DG, Roxburgh CS et al. Colorectal cancer, systemic inflammation, and outcome: staging the tumor and staging the host. Ann Surg 2016;263:326–36. [CrossRef]
7. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149–63. [CrossRef]
8. Cho KM, Park H, Oh DY et al. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. Oncotarget 2017;8:2329–41. [CrossRef]
9. Yu X, Wen Y, Lin Y et al. The value of preoperative Glasgow Prognostic Score and the C-reactive protein to albumin ratio as prognostic factors for long-term survival in pathological T1N0 esophageal squamous cell carcinoma. J Cancer 2018;9:807–15. [CrossRef]
10. Gao GD, Sun B, Wang XB et al. Neutrophil to lymphocyte ratio as prognostic indicator for patients with esophageal squamous cell cancer. Int J Biol Markers 2017;32:e409–14. [CrossRef]
11. Song Y, Yang Y, Gao P et al. The preoperative neutrophil to lymphocyte ratio is a superior indicator of prognosis compared with other inflammatory biomarkers in resectable colorectal cancer. BMC Cancer 2017;17:744. [CrossRef]
12. Lu C, Gao P, Yang Y et al. Prognostic evaluation of platelet to lymphocyte ratio in patients with colorectal cancer. Oncotarget 2017;8:86287–95. [CrossRef]
13. Kinoshita A, Onoda H, Imai N et al. The C-reactive protein/ albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol 2015;22:803–10. [CrossRef]
14. Ishizuka M, Nagata H, Takagi K et al. Clinical significance of the Creactive protein to albumin ratio for survival after surgery for colorectal cancer. Ann Surg Oncol 2016;23:900–7. [CrossRef]
15. Wei XL, Wang FH, Zhang DS et al. A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the Creactive protein/albumin ratio. BMC Cancer 2015;15:350.
16. Chen Z, Shao Y, Fan M et al. Prognostic significance of preoperative C-reactive protein: albumin ratio in patients with clear cell renal cell carcinoma. Int J Clin Exp Pathol 2015;8:14893–900.
17. Haruki K, Shiba H, Shirai Y et al. The C-reactive protein to albumin ratio predicts long-term outcomes in patients with pancreatic cancer after pancreatic resection. World J Surg 2016;40:2254–60. [CrossRef]
18. Liu X, Sun X, Liu J et al. Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol 2015;8:339–45. [CrossRef]
19. Kensuke Kudou, Hiroshi Saeki, Yuichiro Nakashima et al. Creactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer. Journal of Gastroenterology and Hepatology 2018.
20. Ni X-F, Wu J, Ji M, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non–small-cell lung cancer. Asia-Pac J Clin Oncol 2018;1–8.
21. Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007;61:824–33. [CrossRef]
22. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436–44. [CrossRef]
23. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013;13:759–71.
24. McMillan DC. The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev 2013;39:534–40. [CrossRef]
25. Roxburgh CS, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer 2014;110:1409–12. [CrossRef]
26. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011;47:2633–41. [CrossRef]